Intellectual Property Safe Harbor May Be Shrinking After Years Of Growth
This article was originally published in The Gray Sheet
Executive Summary
Device manufacturers developing products with uncertain patent protection status should use data provided during FDA inspections as a benchmark for their potential inclusion in the IP safe harbor, according to RenalTech International VP-Regulatory Affairs Diane Minear
You may also be interested in...
Wesley Jessen Wins PureVision Patent Suit; B&L Weighs Limited Options
Bausch & Lomb is prohibited from selling its PureVision extended-wear contact lenses in the U.S. following a Washington, D.C. federal appeals court ruling Feb. 12
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.